Merkel cell carcinoma is an aggressive skin carcinoma that, when advanced or metastatic, is typically treated with chemotherapy, which often leads to resistance.
The U.S. FDA granted Abbvie Inc. accelerated approval for antibody-drug conjugate (ADC) Teliso-V (telisotuzumab vedotin), newly branded Emrelis, making it the first treatment for previously treated advanced non-small-cell lung cancer with high c-Met protein overexpression.
Gachon University has divulged quinoxaline compounds acting as proto-oncogene tyrosine-protein kinase receptor Ret (RET; CDHF12; PTC) and its mutant inhibitors reported to be useful for the treatment of cancer.
Synnovation Therapeutics Inc. has prepared and tested phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer and more.
Current anticancer approaches, such as antibody or CAR T-cell therapies, rely on targeting tumor-associated antigens rather than tumor-specific antigens, with the consequent on-target, off-tumor effects.
Tumor immunotherapy has become a standard of care for treating various cancers, with immune checkpoint inhibitors targeting the PD-L1/PD-1 axis proving particularly effective. While PD-L1 expression on tumor cells is a predictive biomarker for therapeutic response, emerging evidence highlights the importance of PD-L1 expression on myeloid cells, such as monocytes and dendritic cells (DCs), in shaping the tumor microenvironment and influencing the success of checkpoint blockade.
Critical Path Institute’s Translational Therapeutics Accelerator has invested in the development of QED-203 for advanced and therapy-resistant prostate cancer. Based on research at the University of Queensland’s School of Pharmacy and Pharmaceutical Sciences, QED-203 is being developed by the Queensland Emory Drug Discovery Initiative.
RSS
